Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The most common adverse reactions identified in the Highlights of the Prescribing Information are based on two safety populations. The first is from a pooled safety population of 543 patients with CML or resistant or intolerant Ph+ ALL (OPTIC and PACE studies) who received ICLUSIG as a single agent at a starting dose of 45 mg orally once daily. In this pooled safety population, the most common (>20%) adverse reactions were rash and related conditions, arthralgia, abdominal pain, fatigue, headache, constipation, hypertension, dry skin, hepatotoxicity, fluid retention and edema, pyrexia, pancreatitis/lipase elevation, nausea, hemorrhage, anemia, AOEs and cardiac arrhythmias. The most common Grade 3 or 4 laboratory abnormalities (>20%) were platelet count decreased, neutrophil cell count decreased, and white blood cell decreased.
The second safety population is from 163 patients with newly diagnosed Ph+ ALL (PhALLCON study) who received ICLUSIG in combination with chemotherapy at a starting dose of 30 mg orally once daily. The most common adverse reactions (>20%) included hepatotoxicity, arthralgia, rash and related conditions, headache, pyrexia, abdominal pain, constipation, fatigue, nausea, oral mucositis, hypertension, pancreatitis/lipase elevation, neuropathy peripheral, hemorrhage, febrile neutropenia, fluid retention and edema, vomiting, paresthesia, and cardiac arrhythmias. The most common Grade 3 or 4 laboratory abnormalities (>20%) included decreased white blood cell count, decreased neutrophil cell count, decreased platelet count, decreased lymphocyte cell count, decreased hemoglobin, increased lipase, and increased ALT.
Newly Diagnosed Ph+ ALL
The safety of ICLUSIG was evaluated in PhALLCON, a randomized, active-controlled, multicenter trial conducted in patients with newly diagnosed Ph+ ALL [see Clinical Studies (14)]. Patients received ICLUSIG (n=163) or imatinib 600 mg (n=81) in combination with reduced-intensity chemotherapy followed by continued treatment with ICLUSIG or imatinib as a single agent (imatinib in combination with chemotherapy is not an approved regimen in adult patients). In the ICLUSIG arm, patients received a starting dosage of ICLUSIG 30 mg orally once daily in combination with chemotherapy, with a reduction to 15 mg orally once daily upon achievement of MRD-negative CR at the end of induction. The median duration of exposure was 9.0 months (range: <1 month to 4.2 years) in the ICLUSIG arm and 5.2 months (range: <1 month to 4.4 years) in the imatinib arm.
Patients with uncontrolled hypertension, hypertriglyceridemia, or diabetes and patients with clinically significant, uncontrolled, or active cardiovascular disease, including any history of myocardial infarction, peripheral vascular infarction, revascularization procedure, venous thromboembolism, clinically significant atrial/ventricular tachyarrhythmias, history of myocardial infarction, unstable angina, or congestive heart failure within the 6 months prior to the first dose of ICLUSIG, were excluded.
Serious adverse reactions occurred in 63% of patients receiving ICLUSIG in combination with chemotherapy. Serious adverse reactions in >2% of patients included febrile neutropenia (18%), pyrexia (6%), thrombocytopenia (4.3%), sepsis (3.7%), septic shock (3.7%), anemia (2.5%), hemorrhage (2.5%), neutropenia (2.5%), pancreatitis (2.5%), peripheral neuropathy (2.5%), pneumonia (2.5%) and acute kidney injury (2.5%). Fatal adverse reactions occurred in 6% of patients who received ICLUSIG in combination with chemotherapy, including sepsis (3.7%), sudden death, pneumonitis and respiratory failure (0.6%, each).
Permanent discontinuation of ICLUSIG due to adverse reactions occurred in 13% of patients. Adverse reactions resulting in permanent discontinuation of ICLUSIG in >2% of patients included arterial occlusive events and sepsis.
Dosage modifications (dose interruption or reduction) of ICLUSIG due to adverse reactions occurred in 71% of patients. Adverse reactions leading to dose interruption or reduction of ICLUSIG in >5% of patients included increased ALT, neutropenia, increased lipase, thrombocytopenia, increased AST, febrile neutropenia, and abdominal pain.
Table 4 summarizes the adverse reactions in patients receiving ICLUSIG or imatinib in combination with chemotherapy in PhALLCON.
Table 4: Adverse Reactions (>10%) in Patients with Newly Diagnosed Ph+ ALL in PhALLCON| Adverse Reaction | ICLUSIG 30 mg → 15 mg with Chemotherapy (n = 163) | Imatinib 600 mg with Chemotherapy (n = 81) |
|---|
All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
|---|
| Graded using CTCAE v5.0 |
| Hepatobiliary Disorders |
| Hepatotoxicity | 66 | 30 | 57 | 14 |
| Musculoskeletal and Connective Tissue Disorders |
| Arthralgia
| 47 | 4.3 | 35 | 1.2 |
| Myalgia | 13 | 1.2 | 10 | 1.2 |
| Nervous System Disorders |
| Headache | 45 | 1.8 | 43 | 1.2 |
| Neuropathy peripheral | 33 | 1.2 | 24 | 1.2 |
| Paresthesia | 22 | 0 | 10 | 0 |
| Peripheral sensory neuropathy | 12 | 0 | 12 | 0 |
| Skin and Subcutaneous Tissue Disorders |
| Rash and related conditions | 47 | 1.2 | 33 | 1.2 |
| Gastrointestinal Disorders |
| Abdominal pain
| 43 | 4.9 | 28 | 0 |
| Constipation | 41 | 0.6 | 21 | 1.2 |
| Nausea | 37 | 3.1 | 52 | 7 |
| Oral mucositis | 35 | 4.9 | 30 | 10 |
| Pancreatitis/lipase elevation | 34 | 15 | 37 | 20 |
| Vomiting | 24 | 1.2 | 40 | 2.5 |
| Diarrhea | 20 | 0 | 35 | 2.5 |
| General Disorders |
| Pyrexia | 44 | 4.3 | 26 | 2.5 |
| Fatigue or asthenia | 40 | 2.5 | 38 | 3.7 |
| Fluid retention and edema | 24 | 0.6 | 48 | 3.7 |
| Vascular Disorders |
| Hypertension | 34 | 14 | 15 | 7 |
| Hemorrhage | 31 | 1.8 | 30 | 7 |
| Venous thromboembolic events | 12 | 3.1 | 10 | 2.5 |
| Blood and Lymphatic System Disorders |
| Febrile neutropenia | 28 | 25 | 22 | 20 |
| Metabolism and Nutrition Disorders |
| Impaired glucose tolerance | 20 | 4.9 | 20 | 9 |
| Hyperlipidemia | 16 | 1.2 | 15 | 1.2 |
| Decreased appetite | 10 | 0 | 19 | 3.7 |
| Cardiac Disorders |
| Cardiac arrhythmias | 22 | 2.5 | 17 | 6 |
| Infections |
| Sepsis
| 17 | 12 | 15 | 11 |
| Pneumonia | 11 | 7 | 11 | 6 |
| Respiratory, Thoracic, and Mediastinal Disorders |
| Cough | 17 | 0 | 6 | 0 |
| Dyspnea | 13 | 1.2 | 4.9 | 2.5 |
Clinically relevant adverse reactions in ≤10% of patients receiving ICLUSIG with chemotherapy: urinary tract infection (10%), arterial occlusive events (6%), cardiac failure (6%), and acute kidney injury (4.3%).
Table 5 summarizes the laboratory abnormalities in PhALLCON for patients who received ICLUSIG or imatinib in combination with chemotherapy.
Table 5: Select Laboratory Abnormalities (≥20%) that Worsened from Baseline in Patients with Newly Diagnosed Ph+ ALL in PhALLCON| Laboratory Abnormality | ICLUSIG 30 mg → 15 mg with Chemotherapy (n = 163) | Imatinib 600 mg with Chemotherapy (n = 81) |
|---|
All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
|---|
ALT = alanine aminotransferase, AST = aspartate aminotransferase Graded using CTCAE v5.0 |
| Hematologic Laboratory Tests |
| White blood cell decreased | 79 | 71 | 78 | 70 |
| Lymphocyte cell count decreased | 77 | 61 | 94 | 89 |
| Neutrophil cell count decreased | 66 | 63 | 57 | 53 |
| Platelet count decreased | 65 | 62 | 64 | 53 |
| Hemoglobin decreased | 53 | 38 | 59 | 49 |
| Liver Function Tests |
| ALT increased | 69 | 21 | 62 | 7 |
| AST increased | 53 | 7 | 48 | 6 |
| Alkaline phosphatase increased | 44 | 1.2 | 24 | 0 |
| Total bilirubin increased | 25 | 0.6 | 24 | 0 |
| Direct bilirubin increased | 24 | 4.3 | 24 | 1.2 |
| Pancreatic Enzymes |
| Lipase increased | 60 | 24 | 78 | 38 |
| Amylase increased | 25 | 6 | 35 | 7 |
| Chemistry |
| Calcium decreased | 67 | 3.1 | 69 | 4.9 |
| Phosphate decreased | 58 | 16 | 85 | 36 |
| Potassium decreased | 44 | 10 | 74 | 25 |
| Albumin decreased | 42 | 1.8 | 56 | 0 |
| Glucose increased | 34 | 2.5 | 38 | 2.5 |
| Creatinine increased | 34 | 3.7 | 48 | 4.9 |
| Sodium decreased | 32 | 3.1 | 35 | 3.7 |
| Potassium increased | 31 | 3.7 | 12 | 0 |
| Magnesium decreased | 15 | 0.6 | 31 | 2.5 |
SPL UNCLASSIFIED SECTION
Previously Treated CP-CML
The safety of ICLUSIG was evaluated in OPTIC [see Clinical Studies (14)]. Patients received one of three starting doses of ICLUSIG: 45 mg orally once daily (n=94), 30 mg orally once daily (n=94), or 15 mg orally once daily (n=94). Patients with uncontrolled hypertension or diabetes and patients with clinically significant, uncontrolled, or active cardiovascular disease, including any history of myocardial infarction, peripheral vascular infarction, revascularization procedure, congestive heart failure, venous thromboembolism, or clinically significant atrial/ventricular arrhythmias, were excluded. Only the safety information for the recommended starting dosage (45 mg) is described below. Patients who received a starting dose of ICLUSIG 45 mg orally once daily had a mandatory dose reduction to 15 mg once daily upon achievement of ≤1% BCR::ABL1IS. Of these patients, 76% were exposed for 1 year or longer, 59% were exposed for two years or longer and 43% were exposed to five years or longer. The median time to the response-based dose reduction to 15 mg was 6.4 months (range: 3.1 months to 1.8 years).
Serious adverse reactions occurred in 40% of patients who received ICLUSIG at a starting dose of 45 mg. Serious adverse reactions in >2% of patients included AOEs (13%; of which 2.1% were sudden death), cardiac arrhythmias (9%; of which 2.1% were atrial fibrillation), thrombocytopenia (5%), pyrexia (4.3%), anemia (3.2%), abdominal pain (3.2%), pancreatitis/lipase elevation (2.1%), neutropenia (2.1%), hypertension (2.1%) and hepatotoxicity (2.1%). Fatal adverse reactions occurred in 4 patients (4.3%), including sudden death (2.1%), myocardial infarction (1.1%) and myocardial ischemia (1.1%).
Permanent discontinuation of ICLUSIG due to an adverse reaction occurred in 24% of patients who received ICLUSIG at a starting dose of 45 mg. Adverse reactions which resulted in permanent discontinuation in >2% of patients included AOEs, thrombocytopenia, hypertension, and sudden death.
Dose modifications (dose interruption or reductions) of ICLUSIG due to an adverse reaction occurred in 81% of patients who received ICLUSIG at a starting dose of 45 mg. Adverse reactions which required dose interruptions or reductions in >5% of patients included thrombocytopenia, pancreatitis/lipase elevation, neutropenia, hepatotoxicity, rash and related conditions, anemia, cardiac arrhythmias, AOEs, and cardiac failure.
The most common (>20%) adverse reactions were rash and related conditions, hypertension, hepatoxicity, hyperlipidemia, arthralgia, pancreatitis/lipase elevation, abdominal pain and cardiac arrhythmias. The most common (>20%) Grade 3 or 4 laboratory abnormalities were platelet count decreased and neutrophil cell count decreased.
Table 6 summarizes the adverse reactions in OPTIC for patients who received ICLUSIG at a starting dose of 45 mg.
Table 6: Adverse Reactions (≥10%) in Patients with CP-CML Who Received ICLUSIG at Starting Dose of 45 mg Followed by Reduction to 15 mg After Achievement of ≤1% BCR::ABL1IS in OPTIC| Adverse Reaction | ICLUSIG 45 mg → 15 mg (N = 94) |
|---|
All Grades (%) | Grade 3 or 4 (%) |
|---|
| Graded using CTCAE v5.0 |
| Skin and Subcutaneous Tissue Disorders |
| Rash and related conditions | 47 | 3.2 |
| Dry skin | 12 | 0 |
| Vascular Disorders |
| Hypertension | 37 | 14 |
| Arterial occlusive events | 18 | 7 |
| Hemorrhage | 13 | 2.1 |
| Hepatobiliary Disorders |
| Hepatotoxicity | 34 | 7 |
| Musculoskeletal and Connective Tissue Disorders |
| Arthralgia
| 33 | 0 |
| Metabolism and Nutrition Disorders |
| Hyperlipidemia
| 32 | 4.3 |
| Impaired glucose tolerance
| 10 | 2.1 |
| Gastrointestinal Disorders |
| Abdominal pain
| 31 | 3.2 |
| Pancreatitis/lipase elevation | 29 | 16 |
| Constipation | 15 | 0 |
| Cardiac Disorders |
| Cardiac arrhythmias | 27 | 5 |
| Cardiac failure | 20 | 2.1 |
| Nervous System Disorders |
| Headache | 20 | 0 |
| Neuropathy | 13 | 0 |
| General Disorders and Administration Site Conditions |
| Pyrexia | 18 | 1.1 |
| Fatigue or asthenia | 18 | 1.1 |
| Infections and Infestations |
| Upper respiratory tract infection | 11 | 0 |
| Respiratory Thoracic and Mediastinal Disorders |
| Cough | 10 | 0 |
Clinically relevant adverse reactions in <10% of patients who received ICLUSIG at a starting dose of 45 mg: fluid retention and edema (6%), and hypothyroidism (5%).
Table 7 summarizes the laboratory abnormalities in OPTIC for patients who received ICLUSIG at a starting dose of 45 mg.
Table 7: Select Laboratory Abnormalities (>20%) that Worsened from Baseline in Patients with CP-CML Who Received ICLUSIG at Starting Dose of 45 mg in OPTIC| Laboratory Abnormality | ICLUSIG 45 mg → 15 mg (N = 94) |
|---|
All Grades (%) | Grade 3 or 4 (%) |
|---|
ALT = alanine aminotransferase, AST = aspartate aminotransferase Graded using CTCAE v5.0 (except glucose increased which is graded using CTCAE v4.03) |
| Hematologic Laboratory Tests |
| Platelet count decreased | 66 | 31 |
| Neutrophil cell count decreased | 56 | 22 |
| White blood cell decreased | 54 | 15 |
| Lymphocyte decreased | 45 | 9 |
| Hemoglobin decreased | 38 | 14 |
| Liver Function Tests |
| ALT increased | 53 | 2.1 |
| AST increased | 39 | 1.1 |
| Alkaline phosphatase increased | 31 | 1.1 |
| Chemistry |
| Glucose increased | 53 | 3.2 |
| Triglycerides increased | 50 | 6 |
| Phosphate decreased | 34 | 3.2 |
| Bicarbonate decreased | 30 | 0 |
| Calcium decreased | 21 | 3.2 |
| Pancreatic Enzymes |
| Lipase increased | 40 | 16 |
SPL UNCLASSIFIED SECTION
Previously Treated CML or Ph+ ALL
The safety of ICLUSIG was evaluated in PACE [see Clinical Studies (14)]. Eligible patients had CML or Ph+ ALL whose disease was considered to be resistant or intolerant to prior kinase inhibitor, including those with the BCR::ABL T315I mutation. Patients with uncontrolled hypertriglyceridemia and patients with clinically significant or active cardiovascular disease, including any history of clinically significant atrial/ventricular arrhythmias or history of myocardial infarction, unstable angina, or congestive heart failure within the 3 months prior to the first dose of ICLUSIG, were excluded. Patients received a starting dose of ICLUSIG 45 mg orally once daily (N=449). Dose reductions to 30 mg orally once daily or 15 mg orally once daily were allowed for the management of adverse reactions. After approximately 2 years of follow-up, patients who were still taking a 45 mg orally once daily dose were recommended to undergo a dose reduction in response to the continued occurrence of AOEs and VTEs in the clinical trial [see Warnings and Precautions (5.1)]. At study completion (60 months of follow-up), the median duration of treatment with ICLUSIG was 32 months in patients with CP-CML, 19 months in patients with AP-CML, 2.9 months in patients with BP-CML, and 2.7 months in patients with Ph+ ALL.
Serious adverse reactions occurred in 69% of patients who received ICLUSIG. Serious adverse reactions in >2% of patients included AOEs (20%), pneumonia (10%), cardiac arrhythmias (8%), pancreatitis/lipase elevation (7%), abdominal pain (6%), cardiac failure (6%), hemorrhage (6%), sepsis (5%), VTEs (5%), fluid retention and edema (4.5%), pyrexia (4.5%), secondary malignancies (5%), anemia (3.3%), hypertension (3.1%), thrombocytopenia (3.1%), febrile neutropenia (2.9%), cellulitis (2.7%), and arthralgia (2.2%). Fatal adverse reactions occurred in 9% of patients who received ICLUSIG; the most frequent fatal adverse reactions were AOEs (2%), sepsis (1.6%), and hemorrhage (1.3%).
Permanent discontinuation of ICLUSIG due to an adverse reaction occurred in 21% of CP-CML, 12% of AP-CML, 15% of BP-CML, and 9% of Ph+ ALL patients. The most frequent adverse reactions that led to treatment discontinuation were thrombocytopenia (4.5%) and AOEs (4%).
Dose interruption of ICLUSIG for more than 3 days due to an adverse reaction occurred in 71% of patients and dose reduction of ICLUSIG due to an adverse reaction occurred in 68% of patients. Adverse reactions which required a dosage interruption or dose reduction in >5% of patients included thrombocytopenia (31%), pancreatitis/lipase elevation (17%), abdominal pain (14%), rash and related conditions (14%), neutropenia (14%), hepatotoxicity (12%), AOEs (10%), arthralgia (8%), anemia (7%), ALT increased (6%), and AST increased (5%).
The most common (>20%) non-hematologic adverse reactions were rash and related conditions, arthralgia, abdominal pain, fatigue, constipation, headache, dry skin, fluid retention and edema, hepatotoxicity, hypertension, pyrexia, nausea, hemorrhage, pancreatitis/lipase elevation, AOEs, diarrhea, vomiting, and myalgia.
Table 8 summarizes the adverse reactions in PACE.
Table 8: Adverse Reactions (>10%) in Patients with CML or Ph+ ALL Who Received ICLUSIG in PACE | Adverse Reaction | CP-CML (N = 270) | AP-CML (N = 85) | BP-CML (N = 62) | Ph+ ALL (N = 32) |
|---|
All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
|---|
| Graded using CTCAE v4.03. |
| Skin and Subcutaneous Tissue Disorders |
| Rash and related conditions | 75 | 9 | 68 | 12 | 55 | 7 | 50 | 3.1 |
| Dry skin | 42 | 3.3 | 32 | 1.2 | 26 | 1.6 | 25 | 0 |
| Alopecia | 8 | 0 | 11 | 0 | 8 | 0 | 6 | 0 |
| Musculoskeletal and Connective Tissue Disorders |
| Arthralgia | 61 | 9 | 58 | 6 | 52 | 4.8 | 41 | 0 |
| Myalgia | 24 | 1.1 | 21 | 0 | 18 | 0 | 6 | 0 |
| Muscle spasms | 14 | 0 | 7 | 0 | 4.8 | 0 | 13 | 0 |
| Bone pain | 14 | 0.4 | 13 | 1.2 | 11 | 3 | 9 | 3 |
| Musculoskeletal pain | 11 | 1.5 | 7 | 0 | 8.1 | 0 | 6 | 3 |
| Gastrointestinal Disorders |
| Abdominal pain | 54 | 11 | 49 | 9 | 45 | 13 | 34 | 6 |
| Constipation | 42 | 2.6 | 29 | 2.4 | 27 | 0 | 53 | 3.1 |
| Pancreatitis/lipase elevation | 32 | 19 | 21 | 15 | 19 | 16 | 9 | 6 |
| Nausea | 29 | 0.7 | 32 | 0 | 34 | 1.6 | 22 | 0 |
| Diarrhea | 20 | 0.7 | 29 | 2.4 | 24 | 3.2 | 13 | 3.1 |
| Vomiting | 19 | 1.5 | 27 | 0 | 27 | 1.6 | 25 | 0 |
| Oral mucositis
| 16 | 1.1 | 20 | 1.2 | 24 | 0 | 9 | 3.1 |
| General Disorders |
| Fatigue or asthenia | 44 | 3.7 | 47 | 8 | 36 | 4.8 | 34 | 3.1 |
| Fluid retention and edema | 31 | 3.7 | 37 | 3.5 | 32 | 4.8 | 41 | 6 |
| Pyrexia | 26 | 1.1 | 40 | 7 | 37 | 3.2 | 25 | 0 |
| Chills | 8 | 0 | 12 | 0 | 13 | 1.6 | 9 | 0 |
| Nervous System Disorders |
| Headache | 43 | 3.3 | 31 | 1.2 | 31 | 3.2 | 25 | 0 |
| Neuropathy | 26 | 3.3 | 18 | 2.4 | 13 | 0 | 13 | 0 |
| Dizziness | 17 | 0.4 | 11 | 0 | 4.8 | 0 | 3.1 | 0 |
| Vascular Disorders |
| Hypertension
| 42 | 30 | 53 | 28 | 48 | 6 | 31 | 25 |
| Arterial occlusive events | 31 | 17 | 22 | 12 | 13 | 10 | 13 | 6 |
| Hemorrhage | 23 | 3 | 38 | 12 | 37 | 8 | 31 | 13 |
| Hepatobiliary Disorders |
| Hepatotoxicity | 32 | 10 | 39 | 14 | 34 | 19 | 16 | 13 |
| Cardiac Disorders |
| Cardiac arrhythmias | 19 | 7 | 17 | 4.7 | 24 | 8 | 25 | 6 |
| Cardiac failure | 9 | 5 | 8 | 4.7 | 16 | 10 | 6 | 3.1 |
| Respiratory, Thoracic, and Mediastinal Disorders |
| Cough
| 19 | 0 | 24 | 0 | 21 | 0 | 6 | 0 |
| Dyspnea
| 19 | 3 | 20 | 3.5 | 23 | 6 | 16 | 0 |
| Infections |
| Upper respiratory tract infection
| 14 | 1.1 | 13 | 0 | 13 | 1.6 | 3.1 | 0 |
| Urinary tract infection
| 12 | 2.2 | 14 | 3.5 | 1.6 | 1.6 | 9 | 0 |
| Nasopharyngitis | 12 | 0 | 18 | 0 | 3.2 | 0 | 3.1 | 0 |
| Pneumonia | 8 | 4.8 | 18 | 11 | 18 | 13 | 22 | 16 |
| Cellulitis | 4.4 | 1.9 | 8 | 3.5 | 13 | 4.8 | 0 | 0 |
| Sepsis
| 2.6 | 1.9 | 11 | 6 | 18 | 6 | 28 | 25 |
| Metabolism and Nutrition Disorders |
| Decreased appetite | 13 | 0.4 | 14 | 1.2 | 8 | 0 | 31 | 0 |
| Hyperlipidemia | 13 | 0.7 | 7 | 0 | 3.2 | 0 | 3.1 | 0 |
| Investigations |
| Weight decreased | 10 | 0.4 | 9 | 0 | 4.8 | 0 | 13 | 0 |
| Psychiatric Disorders |
| Insomnia | 11 | 0 | 13 | 0 | 11 | 0 | 13 | 0 |
| Anxiety | 4.8 | 0 | 18 | 0 | 8 | 0 | 6 | 0 |
| Blood and Lymphatic System Disorders |
| Febrile neutropenia | 1.1 | 1.1 | 4.7 | 4.7 | 13 | 13 | 25 | 25 |
Clinically relevant adverse reactions occurring in ≤10% of patients: impaired glucose tolerance (9%), venous thromboembolic events (6%), secondary malignancies (6%), and hypothyroidism (3%).